Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies

 Evotec and Novo Nordisk forms collaboration to develop novel small molecule therapies

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:
  • The partnership will focus on indications like diabetes, obesity, co morbidities including nonalcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic kidney disease
  • Evotec’s drug-discovery platform will be used in ligand-based design to produce products for patients
  • Also the Evotec’s INDiGO platform will be used by Novo, to perform IND registration through pre-clinical studies. Financial details were not disclosed
Click here to read full press release/ article | Ref: Evotec | Image:  Cyprotex

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post